Panacos Pharmaceuticals (PANC) Stock Price, News & Analysis

Company Overview

Panacos Pharmaceuticals, Inc. is a clinical‐stage specialty biopharmaceutical company focused on developing novel drug candidates designed to improve the safety and efficacy of existing therapeutic agents. The company’s proprietary platform centers on advanced liposomal and nanoparticle formulations that aim to enhance targeted delivery and reduce systemic toxicity. Panacos is principally engaged in advancing its pipeline of oncology and dermatology product candidates through preclinical and early‐stage clinical development.

The company’s lead therapeutic candidate is Aroplatin, a liposomal formulation of cisplatin engineered to provide sustained tumor exposure while minimizing the adverse side effects typically associated with platinum‐based chemotherapy. In addition to oncology programs, Panacos is exploring formulation approaches for dermatological indications with the goal of improving topical drug penetration and patient tolerability. These efforts leverage the company’s core expertise in drug encapsulation and controlled‐release technologies.

Headquartered in Wilmington, Delaware, Panacos Pharmaceuticals conducts research and development activities at its U.S. facilities and collaborates with third‐party contract research organizations. While the company’s early‐stage clinical trials have been conducted primarily in North America, Panacos has initiated exploratory partnerships to support future studies in Europe and other regions. The company’s science and management teams include individuals with extensive experience in nanomedicine, oncology drug development and regulatory affairs.

Panacos continues to advance its pipeline through strategic collaborations and milestone‐driven studies, with the objective of achieving proof‐of‐concept data that will support out‐licensing or co‐development partnerships. As a public company trading on the OTC Markets, Panacos maintains a lean operational structure and remains focused on translating its proprietary drug delivery platform into meaningful clinical benefits for patients.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PANC Stock Analysis - Frequently Asked Questions

How do I buy shares of Panacos Pharmaceuticals?

Shares of PANC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PANC
• CIK: N/A
• Web: www.panacos.com
• Phone: (617) 926-1551
• Fax: N/A
• Employees: 41
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A